Condition (MeSH)
Hemangioendothelioma
ClinicalTrials.gov lists 18 trials for Hemangioendothelioma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 18 trials are tagged with Hemangioendothelioma itself; the rest are tagged with a narrower condition beneath it.
When did Hemangioendothelioma trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 4 |
| 2016 | 1 |
| 2012 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 56 months across 10 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemangioendothelioma trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 3 |
| Phase 2 | 9 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 1 |
How many Hemangioendothelioma trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 5 |
| Completed | 8 |
| Terminated | 2 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hemangioendothelioma trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
| BridGene Biosciences Inc. | 1 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 |
| Guerbet | 1 |
| Ikena Oncology | 1 |
Which drugs are being tested for Hemangioendothelioma? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Sirolimus | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ifosfamid | 2 |
| Pazopanib Pill | 2 |
| Doxorubicine | 2 |
| Gemcitabine/Gemzar | 1 |
| Nab-Sirolimus | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hemangioendothelioma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Anemia | 8 | 4 |
| Colitis | 8 | 3 |
| Dyspnea | 8 | 4 |
| Lung infection | 8 | 5 |
| Pleural effusion | 8 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Hemangioendothelioma? (37)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Consensus statement for the diagnosis, treatment, and prognosis of kaposiform hemangioendothelioma. | International journal of cancer | 2025 | Yes |
| Efficacy and safety of high-vs low-dose sirolimus in patients with kaposiform hemangioendothelioma: A randomized clinical trial. | Journal of the American Academy of Dermatology | 2025 | Yes |
| Long-term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges. | International journal of cancer | 2023 | Yes |
| Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial. | Blood | 2022 | Yes |
| Clinical features and management of kaposiform hemangioendothelioma and tufted angioma: Similarities and differences. | Journal of the American Academy of Dermatology | 2022 | Yes |
Showing 5 of 37 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.